Monday, October 12, 2026

Pinduoduo Stock Is 4.26% Up At Session Start On Friday

November 20, 2020

Pinduoduo has been somewhat immune to the crisis with its shares jumping 4.26% to $143.53 at 10:12 EST on Friday, after two sessions in a row of gains. The Nasdaq Stock Market is rising 0.04% to $11895.2, after two successive sessions of losses, on what seems, as yet, a somewhat positive trend trading session on The Nasdaq Stock Market. Pinduoduo's last close was $134.21, above its 52-week high of $116.79. Pinduoduo's sales growth is 73.9% for the present quarter and 74.9% for the next. The company's growth estimates for the current quarter and the next is 15% and 90%, respectively. Pinduoduo's stock is valued at $143.53 at 10:12 EST, way above its 52-week high of 116.79. Pinduoduo's worth is way higher than its 50-day moving average of $84.53 and way higher than its 200-day moving average of $78.68.

Tags

Stock Market Stock Wall Street Stock Price Stock Market Now NASDAQ Market Session PDD IXIC The Nasdaq Stock Market Pinduoduo

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Agentic AI Rewires Enterprise Software: Platform Incumbents, Governance, and a Funded Startup Wave

Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,986

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,986 facts checked against source5,371 source documents archived

Query this data → isubstrate.com

Categories

Tags